Sonidegib Phosphate
FDA-approved product (capsule, oral), marketed as Odomzo.
- Registered studies
- 2
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Basal cell carcinoma
- Neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Hedgehog pathway inhibitors
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA58.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli37.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae26.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis58.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
2registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Sonidegib Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- AfamelanotideExisting use: Erythropoietic protoporphyria65.1% AI-predicted activityagainst MRSA23 registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives64.9% AI-predicted activityagainst MRSALab records exist50+ registered studies
- Imatinib MesylateExisting use: Acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 7 more64.9% AI-predicted activityagainst MRSA50+ registered studies
- Naldemedine TosylateExisting use: Constipation, Constipation disorder64.8% AI-predicted activityagainst MRSA1 registered study
- Vorapaxar SulfateExisting use: Myocardial infarction, Peripheral arterial disease, Recurrent thrombophlebitis and 1 more64.8% AI-predicted activityagainst MRSA15 registered studies
- Rimegepant SulfateExisting use: Migraine disorder64.7% AI-predicted activityagainst MRSA50+ registered studies
- Terlipressin AcetateExisting use: Hepatorenal syndrome, Kidney failure, Renal insufficiency64.6% AI-predicted activityagainst MRSA7 registered studies
- Bremelanotide AcetateExisting use: Mental or behavioural disorder, Physiological sexual disorder, Sexual dysfunction64.5% AI-predicted activityagainst MRSA1 registered study
- Tazemetostat HydrobromideExisting use: Follicular lymphoma, Neoplasm, Sarcoma64.4% AI-predicted activityagainst MRSA3 registered studies
- Isavuconazonium SulfateExisting use: Aspergillosis, Mucormycosis64.3% AI-predicted activityagainst MRSA50+ registered studies
- Nirogacestat HydrobromideExisting use: Gastrointestinal desmoid tumor64.2% AI-predicted activityagainst MRSA1 registered study
- Prasugrel HydrochlorideExisting use: Acute coronary syndrome, Hemorrhage, Intermediate coronary syndrome and 1 more64.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Sonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in China
NCT06880848 · start 2023-06-21
Registered record
- Registry ID
- NCT06880848
- Conditions
- Carcinoma, Basal Cell (BCC)
- Interventions
- Sonidegib Phosphate Capsules
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2023-06-21
- Completion
- 2025-08-26
- Enrolment
- 160
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCarcinoma, Basal Cell (BCC)InterventionSonidegib Phosphate CapsulesPhasePhase 4Registry statusCompletedPilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
NCT02303041 · start 2015-02
Registered record
- Registry ID
- NCT02303041
- Conditions
- Carcinoma, Basal Cell; Recurrent Skin Cancer; Skin Neoplasms; Basal Cell Nevus Syndrome
- Interventions
- Buparlisib; Sonidegib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2015-02
- Completion
- 2017-06
- Enrolment
- 10
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCarcinoma, Basal Cell; Recurrent Skin Cancer; Skin Neoplasms; Basal Cell Nevus SyndromeInterventionBuparlisib; SonidegibPhasePhase 2Registry statusTerminated